# A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome

> **NCT06696261** · PHASE3 · RECRUITING · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 342 (estimated)

## Conditions studied

- Postprandial Distress Syndrome

## Interventions

- **DRUG:** Lianxiaxiaopi Granules
- **DRUG:** a simulated agent of Lianxiaxiaopi Granules

## Key facts

- **NCT ID:** NCT06696261
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 342 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06696261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06696261, "A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06696261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*